Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lichuan Liu

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Oncotarget|June 21, 2019
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Blood|July 19, 2018
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLLSean D Reiff, Elizabeth M Muhowski, Daphne Guinn, et al.
ACS Medicinal Chemistry Letters|August 25, 2020
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target ActivityJames J Crawford, Wendy Lee, Adam R Johnson, et al.
Journal of Medicinal Chemistry|March 12, 2013
Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)Anthony A Estrada, Daniel G Shore, Elizabeth Blackwood, et al.
Journal of Medicinal Chemistry|December 4, 2012
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activityMichael F T Koehler, Philippe Bergeron, Elizabeth Blackwood, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 9, 2016
Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in RatsRebecca I Erickson, Leah K Schutt, Jacqueline M Tarrant, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 12, 2011
Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitorLichuan Liu, Jason S Halladay, Young Shin, et al.
Journal of Medicinal Chemistry|April 19, 2011
Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidineFrederick Cohen, Philippe Bergeron, Elizabeth Blackwood, et al.
Journal of Medicinal Chemistry|February 20, 2018
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical DevelopmentJames J Crawford, Adam R Johnson, Dinah L Misner, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Oncotarget|June 21, 2019
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLLJohn C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Blood|July 19, 2018
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLLSean D Reiff, Elizabeth M Muhowski, Daphne Guinn, et al.
ACS Medicinal Chemistry Letters|August 25, 2020
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target ActivityJames J Crawford, Wendy Lee, Adam R Johnson, et al.
Journal of Medicinal Chemistry|March 12, 2013
Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)Anthony A Estrada, Daniel G Shore, Elizabeth Blackwood, et al.
Journal of Medicinal Chemistry|December 4, 2012
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activityMichael F T Koehler, Philippe Bergeron, Elizabeth Blackwood, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 9, 2016
Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in RatsRebecca I Erickson, Leah K Schutt, Jacqueline M Tarrant, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 12, 2011
Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitorLichuan Liu, Jason S Halladay, Young Shin, et al.
Journal of Medicinal Chemistry|April 19, 2011
Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidineFrederick Cohen, Philippe Bergeron, Elizabeth Blackwood, et al.
Journal of Medicinal Chemistry|February 20, 2018
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical DevelopmentJames J Crawford, Adam R Johnson, Dinah L Misner, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Pageof 6